Glenda Gray
A5011671349- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- Adolescent Sexual and Reproductive Health
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- HIV, Drug Use, Sexual Risk
- HIV/AIDS drug development and treatment
- HIV/AIDS Impact and Responses
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Sex work and related issues
- HIV-related health complications and treatments
- Reproductive tract infections research
- Hepatitis B Virus Studies
- Immune Cell Function and Interaction
- Genital Health and Disease
- Herpesvirus Infections and Treatments
- Cervical Cancer and HPV Research
- Global Maternal and Child Health
- Tuberculosis Research and Epidemiology
- Ethics in Clinical Research
- Hepatitis C virus research
- SARS-CoV-2 detection and testing
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
South African Medical Research Council
2016-2025
University of the Witwatersrand
2016-2025
Perinatal HIV Research Unit
2016-2025
University of Rochester Medical Center
2024
Kingston General Hospital
2023
Corvid Technologies (United States)
2022
University of Zambia
2022
Fred Hutch Cancer Center
2014-2021
Cancer Research Center
2014-2021
Chris Hani Baragwanath Hospital
2010-2021
BackgroundThe Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in prefusion-stabilized conformation.MethodsIn an international, randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned adult participants 1:1 ratio to receive single dose of (5×1010 viral particles) or placebo. The primary end points were efficacy against moderate...
Abstract The SARS-CoV-2 Omicron variant (B.1.1.529) has multiple spike protein mutations 1,2 that contribute to viral escape from antibody neutralization 3–6 and reduce vaccine protection infection 7,8 . extent which other components of the adaptive response such as T cells may still target severe outcomes is unknown. Here we assessed ability react in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, unvaccinated convalescent COVID-19 patients ( n = 70). Between 70% 80% CD4 +...
Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.
The coronavirus disease 2019 (COVID-19) first reported in Wuhan, China December is a global pandemic that threatening the health and wellbeing of people worldwide. To date there have been more than 274 million cases 5.3 deaths. Omicron variant documented City Tshwane, Gauteng Province, South Africa on 9 November 2021 led to exponential increases sharp rise hospital admissions. clinical profile patients admitted at large Tshwane compared with previous waves.466 COVID-19 admissions since 14...
Treatment of latent tuberculosis in patients infected with the human immunodeficiency virus (HIV) is efficacious, but few around world receive such treatment. We evaluated three new regimens for that may be more potent and durable than standard isoniazid treatment.We randomly assigned South African adults HIV infection a positive tuberculin skin test who were not taking antiretroviral therapy to rifapentine (900 mg) plus weekly 12 weeks, rifampin (600 twice (300 daily up 6 years (continuous...
The safety and efficacy of adding antiretroviral drugs to standard zidovudine prophylaxis in infants mothers with human immunodeficiency virus (HIV) infection who did not receive antenatal therapy (ART) because late identification are unclear. We evaluated three ART regimens such infants.
The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis.
A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. canarypox–protein HIV regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection Thailand. An analogous using HIV-1 subtype C potent humoral and cellular responses a phase 1–2a trial South Africa. Efficacy data additional safety were needed for this larger population
The early widespread dissemination of Omicron indicates the urgent need to better understand transmission dynamics this variant, including asymptomatic spread among immunocompetent and immunosuppressed populations. In December 2021, Ubuntu clinical trial, designed evaluate efficacy mRNA-1273 vaccine (Moderna) persons living with HIV (PLWH), began enrolling participants. Nasal swabs are routinely obtained at initial vaccination visit, which requires participants be clinically well receive...
We aimed to assess the effectiveness of a single dose Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers South Africa during two waves African COVID-19 epidemic.
Abstract The extent to which Omicron infection 1–9 , with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured neutralization capacity variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals South Africa infected sublineage BA.1 starting at a median 6 (interquartile range 3–9) days post symptom onset and continuing until last follow-up sample available, 23 19–27) symptoms allow...